ReviewThe Psychiatric quarterly2025
Efficacy and Safety of KarXT (Xanomeline-Trospium; Cobenfy™) in Schizophrenia: A Systematic and Meta-Analysis Review of Randomized Controlled Trials.
Review in The Psychiatric quarterly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia treatments targeting dopamine D2 receptors often fail due to resistance and side effects, highlighting the need for alternatives like KarXT (xanomeline-trospium; Cobenfy™), FDA-approved in September 2024. A systematic review of KarXT would evaluate its efficacy, safety, and potential, guiding future treatment strategies and research. This study systematically evaluated the efficacy and safety of KarXT (xanomeline-trospium; Cobenfy™) in schizophrenia, focusing on its impact on positive and negative symptoms, cognitive function, and adverse effects. Randomized controlled trials on KarXT's efficacy and safety in schizophrenia were selected based on predefined criteria. English-language studies published by August 25, 2025, were identified via major databases. Eligible post hoc analyses from single trials were included. PANSS total scores from five trials were pooled to estimate overall treatment effect. The review followed PRISMA and Cochrane Risk of Bias standards. Seven trials including 1,316 participants (645 KarXT, 671 placebo) consistently showed that KarXT significantly reduced both positive and negative symptoms of schizophrenia in individual trials, reflected in lower PANSS subscale and CGI-S scores. It also improved cognitive function, particularly in patients with severe impairments, and was generally well tolerated, with mild to moderate gastrointestinal adverse events being the most common. Meta-analysis revealed no heterogeneity among studies (Q = 0.26, df = 4, I² = 0.0%), supporting the reliability of the pooled results. Nonetheless, despite study limitations, the pooled meta-analysis showed no significant effect on PANSS total scores, notwithstanding that KarXT clearly benefits specific symptoms and cognition. The results, albeit with some limitations, provided plausible evidence for the efficacy and safety of KarXT in treating schizophrenia.
Indexed as
Identifiers
41045433What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.